HIND
Price
$2.26
Change
+$0.05 (+2.26%)
Updated
Jul 10 closing price
Capitalization
15.79M
32 days until earnings call
Intraday BUY SELL Signals
PHAT
Price
$12.61
Change
+$0.45 (+3.70%)
Updated
Jul 10 closing price
Capitalization
1.01B
25 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HIND vs PHAT

HIND vs PHAT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
HIND vs. PHAT commentary
Jul 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HIND is a Hold and PHAT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 13, 2026
Stock price -- (HIND: $2.26 vs. PHAT: $12.61)
Brand notoriety: HIND and PHAT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HIND: 45% vs. PHAT: 151%
Market capitalization -- HIND: $15.79M vs. PHAT: $1.01B
HIND [@Biotechnology] is valued at $15.79M. PHAT’s [@Biotechnology] market capitalization is $1.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $123.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HIND’s FA Score shows that 0 FA rating(s) are green whilePHAT’s FA Score has 0 green FA rating(s).

  • HIND’s FA Score: 0 green, 5 red.
  • PHAT’s FA Score: 0 green, 5 red.
According to our system of comparison, HIND is a better buy in the long-term than PHAT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HIND’s TA Score shows that 6 TA indicator(s) are bullish while PHAT’s TA Score has 6 bullish TA indicator(s).

  • HIND’s TA Score: 6 bullish, 2 bearish.
  • PHAT’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, HIND is a better buy in the short-term than PHAT.

Price Growth

HIND (@Biotechnology) experienced а -1.74% price change this week, while PHAT (@Biotechnology) price change was +12.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.42%. For the same industry, the average monthly price growth was +13.23%, and the average quarterly price growth was +1883.80%.

Reported Earning Dates

HIND is expected to report earnings on Aug 13, 2026.

PHAT is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (-0.42% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAT($1.01B) has a higher market cap than HIND($15.8M). PHAT YTD gains are higher at: -23.990 vs. HIND (-34.302). HIND has higher annual earnings (EBITDA): -11.07M vs. PHAT (-90.89M). PHAT has more cash in the bank: 181M vs. HIND (8.8M). HIND has less debt than PHAT: HIND (22.5K) vs PHAT (166M). PHAT has higher revenues than HIND: PHAT (205M) vs HIND (153K).
HINDPHATHIND / PHAT
Capitalization15.8M1.01B2%
EBITDA-11.07M-90.89M12%
Gain YTD-34.302-23.990143%
P/E RatioN/AN/A-
Revenue153K205M0%
Total Cash8.8M181M5%
Total Debt22.5K166M0%
FUNDAMENTALS RATINGS
HIND vs PHAT: Fundamental Ratings
HIND
PHAT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5944
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HIND's Valuation (37) in the null industry is in the same range as PHAT (68). This means that HIND’s stock grew similarly to PHAT’s over the last 12 months.

HIND's Profit vs Risk Rating (100) in the null industry is in the same range as PHAT (100). This means that HIND’s stock grew similarly to PHAT’s over the last 12 months.

HIND's SMR Rating (100) in the null industry is in the same range as PHAT (100). This means that HIND’s stock grew similarly to PHAT’s over the last 12 months.

PHAT's Price Growth Rating (44) in the null industry is in the same range as HIND (59). This means that PHAT’s stock grew similarly to HIND’s over the last 12 months.

PHAT's P/E Growth Rating (100) in the null industry is in the same range as HIND (100). This means that PHAT’s stock grew similarly to HIND’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HINDPHAT
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 19 days ago
90%
Bearish Trend 18 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
HIND
Daily Signal:
Gain/Loss:
PHAT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMGIX13.930.07
+0.51%
MFG Core Infrastructure Institutional
TVCFX73.690.37
+0.50%
Thornburg American Opportunities C
JIGFX65.60N/A
N/A
Janus Henderson Overseas I
PSSIX29.87N/A
N/A
Principal SmallCap S&P 600 Index Inst
RERBX58.62-0.02
-0.03%
American Funds EUPAC R-2

HIND and

Correlation & Price change

A.I.dvisor indicates that over the last year, HIND has been loosely correlated with PGEN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HIND jumps, then PGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HIND
1D Price
Change %
HIND100%
+2.26%
PGEN - HIND
46%
Loosely correlated
-3.80%
MTNB - HIND
38%
Loosely correlated
+20.46%
IMMP - HIND
36%
Loosely correlated
-0.36%
ONCY - HIND
31%
Poorly correlated
-3.55%
PHAT - HIND
30%
Poorly correlated
+3.70%
More

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with QCLS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then QCLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
+3.70%
QCLS - PHAT
39%
Loosely correlated
-2.96%
ATRA - PHAT
36%
Loosely correlated
-1.86%
XNCR - PHAT
34%
Loosely correlated
-1.64%
SEPN - PHAT
34%
Loosely correlated
-5.05%
DYN - PHAT
33%
Poorly correlated
-3.50%
More